The Republic of Korea is currently in a situation where reform is inevitable due to the cumulative deficit in medical insurance, and in an era where the aging population will reach 9.5 million in 2023, the prices of medicines that are most closely related to people’s lives are not unrelated to the patent system, and the “duration period of pharmaceutical patents” The “extension system” has a direct causal relationship with the national burden of the medical insurance system.

In this paper, we examine the current problems of the “pharmaceutical patent duration extension system” and suggest ways to improve the system as a change, while also proposing a system in the direction of protecting the interests of domestic pharmaceutical companies and maintaining the legal system at a global level.